<DOC>
	<DOCNO>NCT00123279</DOCNO>
	<brief_summary>The purpose trial evaluate safety preliminary efficacy different dose several exposure time intravitreal microplasmin set par plana vitrectomy vitreomacular traction maculopathy .</brief_summary>
	<brief_title>Intravitreal Microplasmin Patients Undergoing Surgical Vitrectomy</brief_title>
	<detailed_description>Study drug administer mid-vitreous injection . Patients enrol cohort sequential dose/time-escalating fashion . To ensure enrolment evenly balance across eligible condition , enrolment specific underlying disease type cohort cap five ( 5 ) patient .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Patients vitreomacular traction maculopathy vitrectomy indicate , accord principal investigator , include : Macular edema associate vitreomacular traction ( DME , VMTS ) ; Stage IIIII macular hole &lt; 6 month duration since symptom onset ; Demonstration vitreomacular adhesion ( base preoperative optic coherence tomography [ OCT ] ) study eye ; OCT presence posterior hyaloid membrane insert macula , area clear separation visible retina posterior hyaloid . Evidence fibrocellular proliferation characterize whitish epimacular tissue ( surface wrinkle exclusion criterion ) . Patients vitreous hemorrhage precludes either follow : visualization posterior pole visual inspection OR adequate assessment macula either OCT and/or fluorescein angiogram study eye . Patients rhegmatogenous retinal detachment , proliferative vitreoretinopathy ( PVR ) , retinal degenerative change study eye . Patients high myopia aphakia study eye Patients history rhegmatogenous retinal detachment fellow eye family history retinal detachment Patients consider likely require intraocular surgery study eye reason vitreomacular traction maculopathy/macular edema come three month . Patients ocular surgery study eye prior three month . Patients vitrectomy study eye time . Patients history uveitis significant trauma study eye . Patients currently treat glaucoma study eye . Patients laser photocoagulation treatment study eye previous 3 month . Intravitreal injection drug study eye previous 6 month study . Patients pregnant childbearing potential utilizing form contraception acceptable investigator . Patients , investigator 's view , complete visit investigation , include exit visit 6 month . Patients participate investigational drug study within past 30 day . HgA1c &gt; 9 % . Patients hypertension ( either systolic blood pressure [ SBP ] &gt; 170 diastolic blood pressure [ DBP ] &gt; 100 mm Hg ) . Patients lifeexpectancy le 6 month . Patients previously participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>macular hole</keyword>
	<keyword>vitreomacular traction syndrome</keyword>
</DOC>